Advertisement
Australia markets open in 9 hours 36 minutes

  • ALL ORDS

    7,849.40
    +17.50 (+0.22%)
     

  • AUD/USD

    0.6530
    +0.0003 (+0.04%)
     

  • ASX 200

    7,587.00
    +17.10 (+0.23%)
     

  • OIL

    79.11
    +0.11 (+0.14%)
     

  • GOLD

    2,299.00
    -12.00 (-0.52%)
     

  • Bitcoin AUD

    89,610.25
    +1,763.62 (+2.01%)
     

  • CMC Crypto 200

    1,264.17
    -6.57 (-0.52%)
     

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

Zacks Equity Research
·2-min read

Precision BioSciences (DTIL) shares soared 13.4% in the last trading session to close at $15.37. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.6% gain over the past four weeks.

Last week, the company announced robust financial results for the fourth quarter and full-year ended 2023. This might have been driving the share price rally.

This genome editing company is expected to post quarterly loss of $1.80 per share in its upcoming report, which represents a year-over-year change of +74%. Revenues are expected to be $10.5 million, up 19.6% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

ADVERTISEMENT

For Precision BioSciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on DTIL going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Precision BioSciences belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, ChromaDex (CDXC), closed the last trading session 3.7% higher at $3.61. Over the past month, CDXC has returned 116.2%.

For ChromaDex , the consensus EPS estimate for the upcoming report has changed -200% over the past month to -$0.03. This represents no change from what the company reported a year ago. ChromaDex currently has a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Precision BioSciences, Inc. (DTIL) : Free Stock Analysis Report

ChromaDex Corporation (CDXC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research